A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Saved in:
| Title: | A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). |
|---|---|
| Authors: | Capdevila J; Medical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. jcapdevila@vhio.net., Pubul V; Department of Nuclear Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain., Anido U; Molecular Imaging Research Group, Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Walter T; Medical Oncology Department, Edouard Herriot Hospital, Lyon, France., Molina-Cerrillo J; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Alonso-Gordoa T; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Center of Experimental Oncology. Gastrointestinal and Neuroendrocrine Tumors Research Group. Hospital 12 de Octubre Research Institute (Imas12), Madrid, Spain.; Facultad de Medicina, Departamento de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain., San-Roman-Gil M; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Llana B; Nuclear Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Benavent Viñuales M; Medical Oncology Department, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain., Ansquer C; Service de Médecine Nucléaire, CHU de Nantes, Nantes Université, Nantes, France., Baudin E; Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France., Lepage C; Department of Digestive Oncology, University Hospital Dijon, University of Burgundy and Franche Comté, Dijon, France., Del Olmo-García M; Endocrinology and Nutrition Department, Endocrinology, Nutrition and Diet Therapy Research Unit, University and Polytechnic Hospital La Fe, Valencia, Spain.; Departamento de Medicina, Universidad de Valencia, Valencia, Spain., Ruffinelli JC; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Beron A; Service de Médecine Nucléaire, Hôpital Claude Huriez, CHU Lille, Lille, France., Haissaguerre M; Department of Endocrinology, University of Bordeaux, Bordeaux, France., Deshayes E; Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Cedex 5, Montpellier, France., Taïeb D; Department of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital, Marseille, France., Baldari S; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, Messina, Italy., Sansovini M; Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) ''Dino Amadori'', Meldola, Italy., Cingarlini S; Medical Oncology, University and Hospital Trust of Verona, Verona, Italy., Filice A; Servizio Di Medicina Nucleare, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy., Panzuto F; Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy., Álvarez-Álvarez R; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Lousberg L; Service d'Oncologie Médicale CHU Liège, Liège, Belgium., Aboubakar Nana F; Department of Pulmonology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200, Brussels, Belgium.; Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain, 1200, Brussels, Belgium., Hernando J; Medical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., García-Álvarez A; Medical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., García-Burillo A; Medical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Villacampa G; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vandamme T; Department of Oncology and Netwerk, University Hospital Antwerp, Edegem, Belgium.; Center for Oncological Research, Integrated Personalized &Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Fazio N; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy., Durand A; Medical Oncology Department, Edouard Herriot Hospital, Lyon, France. |
| Source: | BMC cancer [BMC Cancer] 2025 Apr 04; Vol. 25 (1), pp. 613. Date of Electronic Publication: 2025 Apr 04. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-025-13941-3 |
